Hepatocyte-like cells derived from induced pluripotent stem cells: A versatile tool to understand lipid disorders

  • Lars E. Larsen
    Department of Experimental Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
    Search for articles by this author
  • Mikhaila A. Smith
    Departments of Genetics and Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
    Search for articles by this author
  • Deepti Abbey
    Departments of Genetics and Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
    Search for articles by this author
  • Amber Korn
    Department of Experimental Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands

    Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
    Search for articles by this author
  • Laurens F. Reeskamp
    Department of Experimental Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands

    Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
    Search for articles by this author
  • Nicholas J. Hand
    Corresponding author. Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Blvd, Smilow Building, SCTR 11-135, Philadelphia, PA, 19104, USA.
    Departments of Genetics and Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
    Search for articles by this author
  • Adriaan G. Holleboom
    Corresponding author. Department of Vascular Medicine, Academic Medical Center, Meibergdreef 15, 1105 AZ, Amsterdam, the Netherlands.
    Department of Experimental Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands

    Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
    Search for articles by this author


      • Hepatocyte like cells (HLCs) can provide an in vitro hepatic cell line with specific variants without gene editing tools.
      • HLCs provide a versatile tool for investigating lipid/lipoprotein metabolism in vitro.
      • HLCs provide a platform to test the biological impact of genetic variants compared to an isogenic control.
      • HLCs provide a platform for high throughput drug testing.


      Dyslipidemias are strongly linked to the development of atherosclerotic cardiovascular disease. Most dyslipidemias find their origin in the liver. In recent years, the differentiation of induced pluripotent stem cells (iPSCs) into hepatocyte-like cells has provided a versatile platform for the functional study of various dyslipidemias, both rare genetic dyslipidemia as well as common lipid disorders associated with insulin resistance or non-alcoholic fatty liver disease. In addition, iPSC-derived hepatocytes can serve as a cell model for developing novel lipid lowering therapies and have the potential of regenerative medicine. This review provides an overview of these developments.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Grundy S.M.
        Pathogenesis of hyperlipoproteinemia.
        J. Lipid Res. 1984; 25: 1611-1618
        • Hess P.L.
        • et al.
        The metabolic syndrome and risk of sudden cardiac death: the atherosclerosis risk in communities study.
        J. Am. Heart Assoc. 2017; 6
        • Nordestgaard B.G.
        Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology.
        Circ. Res. 2016; 118: 547-563
        • Peng J.
        • Luo F.
        • Ruan G.
        • Peng R.
        • Li X.
        Hypertriglyceridemia and atherosclerosis.
        Lipids Health Dis. 2017; 16: 233
        • Ference B.A.
        • et al.
        Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement fromthe European Atherosclerosis Society Consensus Panel.
        Eur. Heart J. 2017; 38: 2459-2472
        • Wang H.H.
        • Garruti G.
        • Liu M.
        • Portincasa P.
        • Wang D.Q.-H.
        Cholesterol and lipoprotein metabolism and atherosclerosis: recent advances in reverse cholesterol transport.
        Ann. Hepatol. 2017; 16: s27-s42
        • Lee S.D.
        • Tontonoz P.
        Liver X receptors at the intersection of lipid metabolism and atherogenesis.
        Atherosclerosis. 2015; 242: 29-36
        • Izem L.
        • et al.
        Effect of reduced low-density lipoprotein receptor level on HepG2 cell cholesterol metabolism.
        Biochem. J. 1998; 329: 81-89
        • Meex S.J.R.
        • Andreo U.
        • Sparks J.D.
        • Fisher E.A.
        Huh-7 or HepG2 cells: which is the better model for studying human apolipoprotein-B100 assembly and secretion?.
        J. Lipid Res. 2011; 52: 152-158
        • Gerets H.H.J.
        • et al.
        Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins.
        Cell Biol. Toxicol. 2012; 28: 69-87
        • Hugo-Wissemann D.
        • Anundi I.
        • Lauchart W.
        • Viebahn R.
        • de Groot H.
        Differences in glycolytic capacity and hypoxia tolerance between hepatoma cells and hepatocytes.
        Hepatology. 1991; 13: 297-303
        • Iyer V.V.
        • Yang H.
        • Ierapetritou M.G.
        • Roth C.M.
        Effects of glucose and insulin on HepG2-C3A cell metabolism.
        Biotechnol. Bioeng. 2010; 107: 347-356
        • Mavri-Damelin D.
        • et al.
        Cells for bioartificial liver devices: the human hepatoma-derived cell line C3A produces urea but does not detoxify ammonia.
        Biotechnol. Bioeng. 2007; 99: 644-651
        • Wiśniewski J.R.
        • Vildhede A.
        • Norén A.
        • Artursson P.
        In-depth quantitative analysis and comparison of the human hepatocyte and hepatoma cell line HepG2 proteomes.
        J. Proteomics. 2016; 136: 234-247
        • Wang Q.
        • Zhao F.
        Glycoproteomic analysis of human hepatoblastoma cell lines using glycopeptide capture and mass spectrometry.
        J. Glycom. Lipidom. 2015; 5
        • Callow M.J.
        • Stoltzfus L.J.
        • Lawn R.M.
        • Rubin E.M.
        Expression of human apolipoprotein B and assembly of lipoprotein(a) in transgenic mice.
        Proc. Natl. Acad. Sci. U.S.A. 1994; 91: 2130-2134
        • Hiroyuki T.
        • et al.
        Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport.
        Circulation. 2007; 116: 1267-1273
        • Strom S.C.
        • Davila J.
        • Grompe M.
        Chimeric mice with humanized liver: tools for the study of drug metabolism, excretion, and toxicity.
        Methods Mol. Biol. 2010; 640: 491-509
        • Takahashi K.
        • Yamanaka S.
        Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.
        Cell. 2006;
        • Laflamme M.A.
        • et al.
        Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts.
        Nat. Biotechnol. 2007; 25: 1015-1024
        • Su S.
        • et al.
        A renewable source of human beige adipocytes for development of therapies to treat metabolic syndrome.
        Cell Rep. 2018; 25 (e9): 3215-3228
        • Si-Tayeb K.
        • et al.
        Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells.
        Hepatology. 2010; 51: 297-305
        • Si-Tayeb K.
        • et al.
        Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia.
        Dis. Model. Mech. dmm. 2015; (022277)
        • Kim K.
        • et al.
        Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells.
        Nat. Biotechnol. 2011; 29: 1117-1119
        • Cayo M.A.
        • et al.
        JD induced pluripotent stem cell-derived hepatocytes faithfully recapitulate the pathophysiology of familial hypercholesterolemia.
        Hepatology. 2012; 56: 2163-2171
        • Graffmann N.
        • et al.
        Modeling nonalcoholic fatty liver disease with human pluripotent stem cell-derived immature hepatocyte-like cells reveals activation of PLIN2 and confirms regulatory functions of peroxisome proliferator-activated receptor alpha.
        Stem Cell. Dev. 2016; 25: 1119-1133
        • Cai J.
        Protocol for directed differentiation of human pluripotent stem cells toward a hepatocyte fate.
        StemBook. 2014;
        • Yi F.
        • et al.
        Establishment of hepatic and neural differentiation platforms of Wilson's disease specific induced pluripotent stem cells.
        Protein Cell. 2012; 3: 855-863
        • Kiamehr M.
        • et al.
        hiPSC-derived hepatocytes closely mimic the lipid profile of primary hepatocytes: a future personalised cell model for studying the lipid metabolism of the liver.
        J. Cell. Physiol. 2019; 234: 3744-3761
        • Cayo M.A.
        • et al.
        A drug screen using human iPSC-derived hepatocyte-like cells reveals cardiac glycosides as a potential treatment for hypercholesterolemia.
        Cell Stem Cell. 2017; 20 (e5): 478-489
        • Omer L.
        • et al.
        CRISPR correction of a homozygous low-density lipoprotein receptor mutation in familial hypercholesterolemia induced pluripotent stem cells.
        Hepatol. Commun. 2017; 1: 886-898
        • Hussain M.M.
        • Shi J.
        • Dreizen P.
        Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly.
        J. Lipid Res. 2003; 44: 22-32
        • Nielsen L.B.
        • et al.
        Genes for apolipoprotein B and microsomal triglyceride transfer protein are expressed in the heart: evidence that the heart has the capacity to synthesize and secrete lipoproteins.
        Circulation. 1998; 98: 13-16
        • Cecatto C.
        • Godoy K.D.S.
        • da Silva J.C.
        • Amaral A.U.
        • Wajner M.
        Disturbance of mitochondrial functions provoked by the major long-chain 3-hydroxylated fatty acids accumulating in MTP and LCHAD deficiencies in skeletal muscle.
        Toxicol. Vitro. 2016; 36: 1-9
        • Hussain M.M.
        • Rava P.
        • Walsh M.
        • Rana M.
        • Iqbal J.
        Multiple functions of microsomal triglyceride transfer protein.
        Nutr. Metab. 2012; 9: 1-16
        • Liu Y.
        • et al.
        Lack of MTTP activity in pluripotent stem cell-derived hepatocytes and cardiomyocytes abolishes apoB secretion and increases cell stress.
        Cell Rep. 2017; 19: 1456-1466
        • Bi X.
        • et al.
        ATP-binding cassette transporter A1 deficiency in human induced pluripotent stem cell-derived hepatocytes abrogates HDL biogenesis and enhances triglyceride secretion.
        EBioMedicine. 2017; 18: 139-145
        • Attie A.D.
        • Kastelein J.P.
        • Hayden M.R.
        Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis.
        J. Lipid Res. 2001; 42: 1717-1726
        • Shen W.-J.
        • Azhar S.
        • Kraemer F.B.
        SR-B1: a unique multifunctional receptor for cholesterol influx and efflux.
        Annu. Rev. Physiol. 2018; 80: 95-116
        • Kinoshita M.
        • et al.
        Scavenger receptor type BI potentiates reverse cholesterol transport system by removing cholesterol ester from HDL.
        Atherosclerosis. 2004; 173: 197-202
        • Acton S.
        • et al.
        Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor. vol. 271. 1996: 518-520
        • Lee M.K.S.
        • Murphy A.J.
        The iPSC awakens ANGPTL3 in tangier disease.
        EBioMedicine. 2017; 18: 15-16
        • Zhu Yiming M
        • et al.
        Association of proprotein convertase subtilisin/kexin type 9 (PCSK9) with cardiovascular risk in primary prevention.
        Arterioscler. Thromb. Vasc. Biol. 2015; 35: 2254-2259
        • Assmann G.
        • van Eckarstein A.
        • H B.
        Familial analphalipoproteinemia: tangier disease.
        in: Scriver The Metabolic & Molecular Basis of Inherited Disease. 2001
        • Zanoni P.
        • et al.
        Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease.
        Science. 2016; 80
        • Pashos E.E.
        • et al.
        Large, diverse population cohorts of hiPSCs and derived hepatocyte-like cells reveal functional genetic variation at blood lipid-associated loci.
        Cell Stem Cell. 2017; 20 (e10): 558-570
        • Hockemeyer D.
        • et al.
        Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases.
        Nat. Biotechnol. 2009; 27: 851
        • Zou J.
        • Maeder M.L.
        • Pruett-miller S.M.
        • Thibodeau-beganny S.
        Resource gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells.
        Stem Cell. 2009; 5: 97-110
        • Hendriks W.T.
        • Warren C.R.
        • Cowan C.A.
        Protocol Review Genome Editing in Human Pluripotent Stem Cells : Approaches , Pitfalls , and Solutions.
        2016: 53-65
        • Ding Q.
        • et al.
        Resource A TALEN genome-editing system for generating human stem cell-based disease models.
        Stem Cell. 2013; 12: 238-251
        • Musunuru K.
        • et al.
        From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus.
        Nature. 2010; 466: 714
        • Kjolby M.
        • et al.
        Article Sort1 , encoded by the cardiovascular risk locus 1p13 . 3 , is a regulator of hepatic lipoprotein export.
        Cell Metabol. 2010; 12: 213-223
        • Hu X.
        • Meng X.
        • Liu Q.
        • Li J.
        • Wang K.
        Increasing the efficiency of CRISPR-Cas9-VQR precise genome editing in rice.
        Plant Biotechnol. J. 2018; 16: 292-297
        • Warren C.R.
        • et al.
        Induced pluripotent stem cell differentiation enables functional validation of GWAS variants in metabolic disease.
        Cell Stem Cell. 2017; 20 (e7): 547-557
        • Friedman S.L.
        • Neuschwander-Tetri B.A.
        • Rinella M.
        • Sanyal A.J.
        Mechanisms of NAFLD development and therapeutic strategies.
        Nat. Med. 2018; 24: 908-922
        • Jozefczuk J.
        • et al.
        A systems biology approach to deciphering the etiology of steatosis employing patient-derived dermal fibroblasts and iPS cells.
        Front. Physiol. 2012; 3 (SEP): 1-18
        • Wruck W.
        • Graffmann N.
        • Kawala M.A.
        • Adjaye J.
        Concise review: current status and future directions on research related to nonalcoholic fatty liver disease.
        Stem Cell. 2017; 35: 89-96
        • Roth G.A.
        • et al.
        Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015.
        J. Am. Coll. Cardiol. 2017;
        • Barbero-Becerra V.J.
        • et al.
        The interplay between hepatic stellate cells and hepatocytes in an in vitro model of NASH.
        Toxicol. Vitro. 2015; 29: 1753-1758
        • Graffmann N.
        • et al.
        Establishment and characterization of an iPSC line from a 58 years old high grade patient with nonalcoholic fatty liver disease (70% steatosis) with homozygous wildtype PNPLA3 genotype.
        Stem Cell Res. 2018; 31: 131-134
        • Coll M.
        • et al.
        Generation of hepatic stellate cells from human pluripotent stem cells enables in vitro modeling of liver fibrosis.
        Cell Stem Cell. 2018; 23 (e7): 101-113
        • Collin de l'Hortet A.
        • et al.
        Generation of human fatty livers using custom-engineered induced pluripotent stem cells with modifiable SIRT1 metabolism.
        Cell Metabol. 2019; 30 (e9): 385-401
        • Ding R.-B.
        • Bao J.
        • Deng C.-X.
        Emerging roles of SIRT1 in fatty liver diseases.
        Int. J. Biol. Sci. 2017; 13: 852-867
        • Wang R.-H.
        • et al.
        Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance.
        J. Clin. Invest. 2011; 121: 4477-4490
        • Ramakrishnan V.M.
        • et al.
        Restoration of physiologically responsive low-density lipoprotein receptor-mediated endocytosis in genetically deficient induced pluripotent stem cells.
        Sci. Rep. 2015; 5: 13231
        • Kerr A.G.
        • et al.
        Episomal nonviral gene therapy vectors slow progression of atherosclerosis in a model of familial hypercholesterolemia.
        Mol. Ther. Nucleic Acids. 2016; 5 (e383–e383)
        • Pattanayak V.
        • Ramirez C.L.
        • Joung J.K.
        • Liu D.R.
        Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection.
        Nat. Methods. 2011; 8: 765
        • Szczepek M.
        • et al.
        Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases.
        Nat. Biotechnol. 2007; 25: 786
        • Galla M.
        • et al.
        Avoiding cytotoxicity of transposases by dose-controlled mRNA delivery.
        Nucleic Acids Res. 2011; 39: 7147-7160
        • Loonstra A.
        • et al.
        Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells.
        Proc. Natl. Acad. Sci. 2001; 98 (LP – 9214): 9209
        • Janbandhu V.
        • Moik D.
        • Fässler R.
        Cre recombinase induces DNA damage and tetraploidy in the absence of LoxP sites.
        Cell Cycle. 2014; 13: 462-470
        • Puschnik A.S.
        • Majzoub K.
        • Ooi Y.S.
        • Carette J.E.
        A CRISPR toolbox to study virus-host interactions.
        Nat. Rev. Microbiol. 2017; 15: 351-364
        • Nayak S.
        • Herzog R.W.
        Progress and prospects: immune responses to viral vectors.
        Gene Ther. 2010; 17: 295-304
        • Shi Y.
        • Inoue H.
        • Wu J.C.
        • Yamanaka S.
        Induced pluripotent stem cell technology: a decade of progress.
        Nat. Rev. Drug Discov. 2017;
        • Singh V.K.
        • Kalsan M.
        • Kumar N.
        • Saini A.
        • Chandra R.
        Induced pluripotent stem cells: applications in regenerative medicine, disease modeling, and drug discovery.
        Front. Cell Dev. Biol. 2015;
        • Chen Y.C.
        • et al.
        Induced pluripotent stem cells and regenerative medicine.
        J. Clin. Gerontol.Geriatr. 2011;
        • Yang J.
        • et al.
        Generation of human liver chimeric mice with hepatocytes from familial hypercholesterolemia induced pluripotent stem cells.
        Stem Cell Reports. 2017;
        • Ordonez M.P.
        • Goldstein L.S.
        Using human-induced pluripotent stem cells to model monogenic metabolic disorders of the Liver.tle.
        Stem Cell. Int. 2014; 32: 298-306
        • Kratochwil N.A.
        • et al.
        Metabolic profiling of human long-term liver models and hepatic clearance predictions from in vitro data using nonlinear mixed-effects modeling.
        AAPS J. 2017; 19: 534-550
        • Chao P.
        • Barminko J.
        • Novik E.
        • Han Y.
        • Maguire Timothy
        • Cheng K.-C
        Prediction of human hepatic clearance using an in vitro plated hepatocyte clearance model.
        Drug Metabol. Lett. 2009; 3: 296-307
        • Fiorotto R.
        • et al.
        Liver diseases in the dish: iPSC and organoids as a new approach to modeling liver diseases.
        Biochim. Biophys. Acta - Mol. Basis Dis. 2019; 1865: 920-928
        • Schwartz R.E.
        • Fleming H.E.
        • Khetani S.R.
        • Bhatia S.N.
        Pluripotent stem cell-derived hepatocyte-like cells.
        Biotechnol. Adv. 2014;
        • Shan J.
        • et al.
        Identification of small molecules for human hepatocyte expansion and iPS differentiation.
        Nat. Chem. Biol. 2013; 9: 514-520
        • Takebe T.
        • et al.
        Vascularized and functional human liver from an iPSC-derived organ bud transplant.
        Nature. 2013; 499: 481
        • Shlomai A.
        • et al.
        Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems.
        Proc. Natl. Acad. Sci. U.S.A. 2014; 111: 12193-12198
        • Camp J.G.
        • et al.
        Multilineage communication regulates human liver bud development from pluripotency.
        Nature. 2017; 546: 533
        • Vunjak-Novakovic G.
        • Bhatia S.
        • Chen C.
        • Hirschi K.
        HeLiVa platform: integrated heart-liver-vascular systems for drug testing in human health and disease.
        Stem Cell Res. Ther. 2013; 4 (S8–S8)
        • Mallanna S.K.
        • Cayo M.A.
        • Twaroski K.
        • Gundry R.L.
        • Duncan S.A.
        Mapping the cell-surface N-glycoproteome of human hepatocytes reveals markers for selecting a homogeneous population of iPSC-derived hepatocytes.
        Stem Cell Reports. 2016;
        • Godoy P.
        • et al.
        Gene networks and transcription factor motifs defining the differentiation of stem cells into hepatocyte-like cells.
        J. Hepatol. 2015;